

wherein

- $X_1 = N$ and $X_2 = A$;
 $X_1 = N$ and $X_2 = T$;
 $X_1 = S$ and $X_2 = G$;
5 $X_1 = H$ and $X_2 = G$;
 $X_1 = D$ and $X_2 = G$; or
 $X_1 = H$ and $X_2 = A$.

In one aspect, the present disclosure refers to an antibody that binds human
 10 CD3 which antibody comprises a heavy chain and light chain wherein said
 heavy chain comprises a variable region that comprises the amino acid
 sequence:

QVQLV QSGGG VVQPG RSLRL SCVAS GFTFS SYGMH WVRQA PGKGL EWVAA
 IWYX₁X₂RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY
 15 CTRGT GYNWF DPWGQ GTLVT VSS

with 0-5 amino acid insertions, deletions, substitutions, additions or a
 combination thereof at one or more positions other than the position
 indicated by X_1X_2 and leaving H35, Y102, N103, and W104 unchanged;
 wherein

- 20 $X_1 = N$ and $X_2 = A$;
 and wherein said light chain comprises light chain CDR1 amino
 acid sequence QSISSY, light chain CDR2 amino acid sequence AAS, and
 light chain CDR3 amino acid sequence QQSYSTP, according to IMGT.

25 In another example, the present disclosure refers to an antibody that binds
 human CD3 which antibody comprises a heavy chain and light chain
 wherein said heavy chain comprises a variable region that comprises the
 amino acid sequence:

Claims

1. An antibody that binds human CD3 which antibody comprises a heavy chain and light chain wherein said heavy chain comprises a variable region that comprises the amino acid sequence:

QVQLV QSGGG VVQPG RSLRL SCVAS GFTFS SYGMH WVRQA PGKGL EWVAA
IWYX₁X₂RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT
GYNWF DPWGQ GTLVT VSS

with 0-5 amino acid insertions, deletions, substitutions, additions or a combination thereof at one or more positions other than the position indicated by X₁X₂ and leaving H35, Y102, N103, and W104 unchanged;

wherein X₁ = N and X₂ = A;

and wherein said light chain comprises light chain CDR1 amino acid sequence QSISSY, light chain CDR2 amino acid sequence AAS, and light chain CDR3 amino acid sequence QQSYSTP, according to IMGT.

2. The antibody of claim 1, wherein the antibody comprises a heavy chain variable region that comprises the amino acid sequence

QVQLVQSGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAAI
WYNARKQEYIDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCTRGTGYN
WFDPWGQGTLVTVSS.

3. The antibody of claim 1, wherein the antibody comprises a heavy chain variable region that comprises the amino acid sequence

QVQLVQSGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAAI
WYNARKQEYND SVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCTRGTGY
NWFPWGQGTLVTVSS.

4. The antibody of claim 1, wherein the antibody comprises a heavy chain variable region that comprises the amino acid sequence

QVQLVQSGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAAI
WYNARKQEYRDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCTRGTGY
NWFDPPWGQGTLVTVSS.

5. The antibody of claim 1, wherein the antibody comprises a heavy chain variable region that comprises the amino acid sequence

QVQLVQSGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAAI
WYNARKQDYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCTRGTGY
NWYDPWGQGTLVTVSS.

6. The antibody of claim 1, wherein the antibody comprises a heavy chain variable region that comprises the amino acid sequence

QVQLVQSGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAAI
WYNARKQEYLD SVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCTRGTGY
NWFDPPWGQGTLVTVSS.

7. The antibody of claim 1, wherein the antibody comprises a heavy chain variable region that comprises the amino acid sequence

QVQLVQSGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAQI
WYNARKQEYSDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCTRGTGY
NWFDPPWGQGTLVTVSS.

8. The antibody of claim 1, wherein the antibody comprises a heavy chain variable region that comprises the amino acid sequence

QVQLVQSGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAAI
WYNARKQEYSDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCTRGTGY
NWFDPPWGQGTLVTVSS.

9. The antibody of any one of claims 1-8, wherein said light chain is a light chain comprising a common light chain variable region.

10. The antibody of claim 9, wherein said common light chain variable region comprises an O12 / IgV κ 1-39 light chain variable region.
11. The antibody of claim 10, wherein said light chain variable region is a germline O12 / IgV κ 1-39*01 variable region.
12. The antibody of claim 11, wherein the light chain variable region comprises a kappa light chain IgV κ 1-39*01/IGJ κ 1*01 or IgV κ 1-39*01/IGJ κ 5*01.
13. The antibody of claim 12, wherein the light chain variable region comprises a germline kappa light chain IgV κ 1-39*01/IGJ κ 1*01 or IgV κ 1-39*01/IGJ κ 5*01.
14. The antibody of any one of claims 1-10, wherein said light chain variable region comprises the amino acid sequence
DIQMT QSPSS LSASV GDRVT ITCRA SQSIS SYLNW YQQKP GKAPK LLIYA
ASSLQ SGVPS RFSGS GSGTD FTLTI SSLQP EDFAT YYCQQ SYSTP PTFGQ
GTKVE IK or DIQMT QSPSS LSASV GDRVT ITCRA SQSIS SYLNW YQQKP
GKAPK LLIYA ASSLQ SGVPS RFSGS GSGTD FTLTI SSLQP EDFAT YYCQQ
SYSTP PITFG QGTRL EIK with 0-5 amino acid insertions, deletions,
substitutions, additions or a combination thereof, wherein the amino acid
insertions, deletions, substitutions, additions or a combination thereof, are not in
the CDR regions.
15. The antibody of any one of claims 1-14, which is a bispecific antibody.
16. The bispecific antibody of claim 15, comprising a H/L chain combination of any one of claims 1-14, and a H/L chain combination that binds a tumor-antigen.
17. The bispecific antibody of claim 16, wherein said H/L chain combination that binds a tumor-antigen binds CLEC12A.

18. The antibody or bispecific antibody of claims 1-17, which is a human or humanized antibody.
19. The bispecific antibody of any one of claims 15-18, comprising two different immunoglobulin heavy chains with compatible heterodimerization domains.
20. The bispecific antibody of claim 19, wherein said compatible heterodimerization domains are compatible immunoglobulin heavy chain CH3 heterodimerization domains.
21. The bispecific antibody of any one of claims 15-20, wherein said bispecific antibody is an IgG antibody with a mutant CH2 and/or lower hinge domain such that interaction of the bispecific IgG antibody to a Fc-gamma receptor is reduced.
22. The bispecific antibody of claim 21, wherein the mutant CH2 and/or lower hinge domain comprise an amino substitution at position 235 and/or 236.
23. The bispecific antibody of claim 21 or 22, wherein the mutant CH2 and/or lower hinge domain comprise an L235G and/or G236R substitution.
24. The bispecific antibody of any one of claims 15-23, comprising a common light chain.
25. The antibody of any one of claims 1-24, for use in the treatment of a subject in need thereof.